

Catalog# BP- 50567

Mogamulizumab Biosimilar (CCR4 Monoclonal Antibody)

Matuzumab Biosimilar uses the same protein sequences as the therapeutic antibody matuzumab.

Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).

Product Details	
CAS No.	1159266-37-1
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Mogamulizumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human CC chemokine receptor 4 (CCR4)
Purity	>95%
Molecular Weight	146.44 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.